Direct Oral Anticoagulants for Cancer‐Associated Venous Thromboembolism in Hematologic Malignancies: A Comprehensive Review
European Journal of Haematology · 2026-05 · 116 (5) · 512-521
DOI: 10.1111/ejh.70130 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift European Journal of Haematology, online erschienen am 02.02.2026. Verfasst von Yuli Zhu und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of General Medicine (Intensive Care Unit), Shaoxing Seventh People's Hospital (Affiliated Mental Health Center, Medical College of Shaoxin…. Hauptthemen laut MEDLINE: Hematologic Neoplasms, Venous Thromboembolism, Anticoagulants. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 78 Literaturangaben. Gefördert von: the Jiebang Guashuai Project of Shaoxing People's Hospital, the Cultivation of High-level Innovative Health Talents Program of Zhejiang Province, Shaoxing Health Science and Technology Program.
Themen: Thromboseprophylaxe
Abstract (Originalsprache)
Venous thromboembolism presents a critical complication in hematologic malignancies, profoundly affecting patient outcomes. Traditional anticoagulant options, low‐molecular‐weight heparin and vitamin K antagonists, encounter significant limitations, especially concerning bleeding risks exacerbated by chemotherapy‐induced thrombocytopenia. Direct oral anticoagulants (DOACs), including factor Xa inhibitors (apixaban, rivaroxaban, edoxaban) and thrombin inhibitors (dabigatran), have emerged as appealing alternatives due to their ease of use, predictable pharmacokinetics, and reduced monitoring requirements. However, their safety and optimal use remain uncertain in hematologic malignancies due to underrepresentation in clinical trials and specific bleeding risks. This review comprehensively summarizes current evidence regarding DOAC safety, efficacy, and clinical management considerations in leukemia, lymphoma, multiple myeloma, and myeloproliferative neoplasms. It emphasizes individualized anticoagulation strategies, highlights existing evidence gaps, and outlines future research priorities, particularly the safe application of DOACs in severe thrombocytopenia and interactions with targeted therapies. Ultimately, tailored anticoagulant approaches are essential to optimizing patient outcomes in this complex patient population.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of General Medicine (Intensive Care Unit), Shaoxing Seventh People's Hospital (Affiliated Mental Health Center, Medical College of Shaoxing University), Shaoxing, Zhejiang, People's Republic of China.
- Department of Vascular and Hernia Surgery, Shaoxing People's Hospital, Shaoxing, Zhejiang, People's Republic of China.
- School of Medicine, Shaoxing University, Shaoxing, Zhejiang, People's Republic of China.
- Department of Hematology, Shaoxing People's Hospital, Shaoxing, Zhejiang, People's Republic of China.
ORCID-Profile: Chao Xu, Leihua Fu, Weiying Feng, Jieni Yu
Förderung
- the Jiebang Guashuai Project of Shaoxing People's Hospital
- the Cultivation of High-level Innovative Health Talents Program of Zhejiang Province
- Shaoxing Health Science and Technology Program
Zitieren
APA
Zhu, Y., Xu, C., Chen, Z., Fu, L., Feng, W., & Yu, J. (2026). Direct Oral Anticoagulants for Cancer‐Associated Venous Thromboembolism in Hematologic Malignancies: A Comprehensive Review. European Journal of Haematology, 116(5), 512-521. https://doi.org/10.1111/ejh.70130
Vancouver
Zhu Y, Xu C, Chen Z, Fu L, Feng W, Yu J. Direct Oral Anticoagulants for Cancer‐Associated Venous Thromboembolism in Hematologic Malignancies: A Comprehensive Review. European Journal of Haematology. 2026;116(5):512-521. doi:10.1111/ejh.70130
BibTeX
@article{Zhu2026,
author = {Zhu, Yuli and Xu, Chao and Chen, Zhe and Fu, Leihua and Feng, Weiying and Yu, Jieni},
title = {Direct Oral Anticoagulants for Cancer‐Associated Venous Thromboembolism in Hematologic Malignancies: A Comprehensive Review},
journal = {European Journal of Haematology},
year = {2026},
volume = {116},
number = {5},
pages = {512--521},
doi = {10.1111/ejh.70130}
}
EUVIMED